[{"orgOrder":0,"company":"4Moving Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Liraglutide","moa":"GLP-1 receptor","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"4Moving Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"4Moving Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"4Moving Biotech \/ Inapplicable"},{"orgOrder":0,"company":"4Moving Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Liraglutide","moa":"GLP-1 receptor","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"4Moving Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"4Moving Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"4Moving Biotech \/ Inapplicable"},{"orgOrder":0,"company":"4Moving Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Liraglutide","moa":"GLP-1 receptor","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"4Moving Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"4Moving Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"4Moving Biotech \/ Inapplicable"},{"orgOrder":0,"company":"4Moving Biotech","sponsor":"French Government","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Peptide","year":"2025","type":"Funding","leadProduct":"Liraglutide","moa":"GLP-1 receptor","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"4Moving Biotech","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.01,"dosageForm":"Intra-articular Injection","sponsorNew":"4Moving Biotech \/ French Government","highestDevelopmentStatusID":"6","companyTruncated":"4Moving Biotech \/ French Government"}]

Find Clinical Drug Pipeline Developments & Deals by 4Moving Biotech

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : The funding aims to advance the clinical dvelopment of company's lead product 4P004 (liraglutide), which is being evaluated for the treatment of knee osteoarthritis.

                          Product Name : 4P004

                          Product Type : Peptide

                          Upfront Cash : Undisclosed

                          April 07, 2025

                          Lead Product(s) : Liraglutide

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase I

                          Sponsor : French Government

                          Deal Size : $8.3 million

                          Deal Type : Funding

                          blank

                          02

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : 4P004 (intraarticular liraglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist, which is indicated for the treatment of patients with knee osteoarthritis.

                          Product Name : 4P004

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          October 06, 2024

                          Lead Product(s) : Liraglutide

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : 4P004, a GLP1 analog, is a novel first-in-class drug candidate addressing a high unmet medical need. The purpose is to potentially change the natural course of osteoarthritis to prevent long-term disability.

                          Product Name : 4P004

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          October 19, 2023

                          Lead Product(s) : Liraglutide

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : 4P004 is a novel first-in-class drug candidate addressing a high unmet medical need that is the absence of a curative treatment for osteoarthritis. 4P004 is a disease-modifying OA drug (DMOAD) candidate.

                          Product Name : 4P004

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          October 14, 2022

                          Lead Product(s) : Liraglutide

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank